Jakobsen M, Schaug J, Storebo O, Austin S, Nielsen J, Simonsen E
BMJ Open. 2025; 15(1):e085956.
PMID: 39819922
PMC: 11751990.
DOI: 10.1136/bmjopen-2024-085956.
Carroll A, Robinson D, Kane J, Kordon A, Bannon J, Walunas T
Front Health Serv. 2024; 4:1385398.
PMID: 39469435
PMC: 11513390.
DOI: 10.3389/frhs.2024.1385398.
Madsen N, Sorensen M, Danielsen A, Hojlund M, Rohde C, Kohler-Forsberg O
Acta Psychiatr Scand. 2024; 151(1):69-80.
PMID: 39379169
PMC: 11608811.
DOI: 10.1111/acps.13760.
Parkes S, Mantell B, Oloyede E, Blackman G
Schizophr Bull Open. 2024; 3(1):sgac042.
PMID: 39144802
PMC: 11205966.
DOI: 10.1093/schizbullopen/sgac042.
Ali M, Amirthalingam P, Veeramani V, Alasiri A, Alsalimi M, Alatawi F
Cureus. 2024; 16(2):e54927.
PMID: 38544646
PMC: 10971419.
DOI: 10.7759/cureus.54927.
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review.
Smessaert S, Detraux J, Desplenter F, De Hert M
CNS Drugs. 2024; 38(2):105-123.
PMID: 38236524
DOI: 10.1007/s40263-023-01054-z.
Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.
Kelly D, Glassman M, Wonodi I, Vyas G, Richardson C, Nwulia E
Schizophr Res. 2023; 268():312-322.
PMID: 37633776
PMC: 10891303.
DOI: 10.1016/j.schres.2023.08.002.
[Safety aspects during treatment with clozapine. : Monitoring and rechallenge - a narrative review].
Berger S, Hofer A
Neuropsychiatr. 2023; 37(3):130-135.
PMID: 37389803
PMC: 10491511.
DOI: 10.1007/s40211-023-00473-0.
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.
Qubad M, Bittner R
Ther Adv Psychopharmacol. 2023; 13:20451253231158152.
PMID: 36994117
PMC: 10041648.
DOI: 10.1177/20451253231158152.
De Novo Seizures, Obsessive Compulsive Symptoms and Neutropenias in Patients on Clozapine: A Retrospective Cohort Study.
Chichra A, Varughese N, Innamuri R
Indian J Psychol Med. 2023; 45(1):33-37.
PMID: 36778619
PMC: 9896117.
DOI: 10.1177/02537176221140496.
Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis.
Kuzo N, Haen E, Ho D, Takeuchi H, Piras M, Eap C
Eur Arch Psychiatry Clin Neurosci. 2022; 273(7):1567-1578.
PMID: 36580106
PMC: 10465369.
DOI: 10.1007/s00406-022-01542-1.
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.
Kamei H
Medicina (Kaunas). 2022; 58(11).
PMID: 36363541
PMC: 9692600.
DOI: 10.3390/medicina58111584.
Managing treatment resistance in schizophrenia: A joint study in Hong Kong and Singapore.
Zheng S, Chan S, Lee J
Front Psychiatry. 2022; 13:1005373.
PMID: 36339860
PMC: 9631784.
DOI: 10.3389/fpsyt.2022.1005373.
Iranian psychiatrists' attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey.
Rezaie L, Nazari A, Safari-Faramani R, Shohaimi S, Khazaie H
BMC Psychiatry. 2022; 22(1):534.
PMID: 35933353
PMC: 9357336.
DOI: 10.1186/s12888-022-04179-5.
Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot Study.
Kylleso L, Smith R, Wollmann B, Karlstad O, Andreassen O, Molden E
J Clin Psychopharmacol. 2022; 42(5):470-474.
PMID: 35916581
PMC: 9426748.
DOI: 10.1097/JCP.0000000000001585.
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.
Correll C, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppala N
CNS Drugs. 2022; 36(7):659-679.
PMID: 35759211
PMC: 9243911.
DOI: 10.1007/s40263-022-00932-2.
Treatment strategies for clozapine-induced hypotension: a systematic review.
Tanzer T, Brouard T, Pra S, Warren N, Barras M, Kisely S
Ther Adv Psychopharmacol. 2022; 12:20451253221092931.
PMID: 35633931
PMC: 9136453.
DOI: 10.1177/20451253221092931.
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study.
Johannsen C, Petersen T, Nielsen J, Jorgensen A, Jimenez-Solem E, Fink-Jensen A
Ther Adv Psychopharmacol. 2022; 12:20451253211072341.
PMID: 35273789
PMC: 8902187.
DOI: 10.1177/20451253211072341.
Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics.
Sharma S, Kopelovich S, Janjua A, Pritchett C, Broussard B, Dhir M
Schizophr Bull Open. 2021; 2(1):sgab043.
PMID: 34676369
PMC: 8521287.
DOI: 10.1093/schizbullopen/sgab043.
Patients' and psychiatrists' perspectives on clozapine treatment-a scoping review protocol.
Jakobsen M, Storebo O, Austin S, Nielsen J, Simonsen E
BMJ Open. 2021; 11(10):e054308.
PMID: 34620673
PMC: 8499327.
DOI: 10.1136/bmjopen-2021-054308.